



January 30, 2015

## Corium to Present at the 2015 Leerink Global Healthcare Conference

MENLO PARK, Calif., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference, Wednesday, February 11, 2015 at the Waldorf Astoria New York hotel.

The Corium presentation will begin at 1:00 p.m. Eastern time. Investors may access the live webcast of the presentation by visiting the Investors section of the Corium website at [www.coriumgroup.com](http://www.coriumgroup.com). A webcast will be archived on the Corium website for four weeks following the presentation.

### About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders. For further information, please visit [www.coriumgroup.com](http://www.coriumgroup.com).

CONTACT: Investor and Media Contact:

Karen L. Bergman

BCC Partners

kbergman@bccpartners.com

(650) 575-1509